Theravance to present analyses of ampreloxetine and neurogenic orthostatic hypotension at the 2025 international msa congress

Dublin , april 28, 2025 /prnewswire/ -- theravance biopharma, inc. ("theravance biopharma" or the "company") (nasdaq: tbph) today announced that analyses of the initial phase 3 program of ampreloxetine (studies 169 and 170) will be presented at the international msa congress, taking place may 9-11, 2025, in boston, massachusetts.  these analyses support the company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (noh) in patients with multiple system atrophy (msa).
MSA Ratings Summary
MSA Quant Ranking